Real-life study shows Sativex effectively reduces MS spasticity and related symptoms.
Real-world use of Sativex, an oral spray cannabinoid treatment, was associated with a self-reported easing of spasticity and related symptoms for people with multiple sclerosis (MS), according to a recent study in Austria. Most patients (87.5%) said they were at least partly satisfied with the therapy after three months of its use, in contrast to about 30% who were satisfied with previous antispasticity treatments.